Under a definitive merger agreement, Roche will acquire outstanding shares of Foundation's common stock for $137 per share.

Mayo Clinic researchers found that mutations in these genes could be found in nearly 6 percent of patients and argued for germline genetic testing for patients.

Researchers provided genetic diagnoses for about 68 percent of their primary antibody deficiency cohort, which altered clinical management in about half of them.

Businesses can now apply for a share of the funds to develop new technologies that increase the UK's capacity to carry out genomic analysis.

A deep RNA sequencing analysis of adipose tissue from lean and obese individuals highlighted new and previously annotated human long intergenic noncoding RNAs.

The researchers designed a transcriptome sequencing assay that identifies clinically relevant gene fusions in 541 genes.

The researchers identified 669 and quantified 332 proteins in single cells, making this one of the most comprehensive mass spec-based experiments of its kind.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

The Economist writes that an increasing number of scientific journals don't do peer review.

In Science this week: genetic overlap among many psychiatric disorders, and more.

In silico molecular biology tools, electronic lab notebooks, and systems for registration,
sample management, workflow management, and request management form the
foundation of informatics for biologics R&D.

When building out their informatics, most R&D organizations evaluate these solutions
independently, by checking off a list of required features. This is a good starting point, but
what are you missing by not evaluating the platform capabilities of these solutions?

The BD Rhapsody Single-Cell Analysis System empowers and streamlines single-cell research with a complete system of tools, including reagents and analysis software, that work together to meet neuroscience experimental needs. Neuroscientists’ ability to identify and characterize individual cells in the nervous system opens the door to finding pathogenic cells, regenerative cells, and pathways that drug manufacturers can exploit for the discovery of therapeutics for neurodegenerative disease.

Highly predictive patient-derived xenograft (PDX) models can predict clinical efficacy for oncology drug candidates better than traditional cell line-derived preclinical models. This white paper describes how PDX models can be used in Mouse Clinical Trials, upending the traditional paradigm in animal studies and providing a better perspective of patient-to-patient heterogeneity.